ArticleBMB reports2025
Functional analysis of secreted tissue inhibitor of metalloproteinases-1 from adult human neural stem cells (ahNSCs) for regeneration and neuroprotection.
Article in BMB reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adult human neural stem cell (ahNSC)-conditioned medium (CM) contains various secreted factors that promote tissue repair and neuroprotection. This study aimed to identify the key secreted proteins in ahNSC-CM and investigate the role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in wound healing, angiogenesis, and neuroprotection against oxygenglucose deprivation. Cytokine array and liquid chromatography- tandem mass spectrometry analysis of ahNSC-CM revealed that monocyte chemoattractant protein-1 (MCP-1) and TIMP-1 were highly abundant. Enzyme-linked immunosorbent assay confirmed the enrichment of both in ahNSC-CM. Recombinant human TIMP-1 promoted wound closure and angiogenesis, whereas neutralizing TIMP-1 in ahNSC-CM attenuated these effects, with wound healing involving the extracellular signalregulated kinases 1 and 2 and protein kinase B pathways. Furthermore, ahNSC-CM protected neurons from oxygen-glucose deprivation-induced apoptosis, and this neuroprotective effect was partially reversed by TIMP-1 neutralization, potentially through the modulation of B-cell lymphoma 2 and B-cell lymphoma 2-associated X protein expression. Consistent with findings in ahNSCs, where monocyte chemoattractant protein-1 is highly expressed and contributes to pro-angiogenic effects, our study highlights the importance of secreted factors such as TIMP-1 in the therapeutic potential of ahNSC-CM. These findings suggest that TIMP-1 is a significant component of ahNSC-CM and contributes to its regenerative and neuroprotective properties. [BMB Reports 2025; 58(10): 444-449].
Indexed as
Identifiers
40916645PMC12576409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.